Legal Representation
Attorney
                                            Brian A. Tollefson
                                        USPTO Deadlines
                                Next Deadline
                            
                            
                                    
                                        
                                        923 days remaining
                                    
                            
                        Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2018-05-15)
                                    
                                    Due Date
                                
                                
                                    May 15, 2028
                                
                            
                                        
                                        Grace Period Ends
                                    
                                    
                                        November 15, 2028
                                    
                                Application History
46 events| Date | Code | Type | Description | Documents | 
|---|---|---|---|---|
| Aug 18, 2025 | INPR | P | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | Loading... | 
| Jun 13, 2025 | NA75 | E | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | Loading... | 
| Jun 13, 2025 | C75A | O | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | Loading... | 
| Jun 5, 2025 | EROP | I | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | Loading... | 
| Dec 18, 2024 | PR75 | O | POST REGISTRATION ACTION MAILED - SEC. 71 & 15 | Loading... | 
| Dec 16, 2024 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... | 
| May 14, 2024 | ES75 | I | TEAS SECTION 71 & 15 RECEIVED | Loading... | 
| May 15, 2023 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | Loading... | 
| Oct 24, 2022 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... | 
| Oct 24, 2022 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... | 
| Oct 24, 2022 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... | 
| Oct 24, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... | 
| Oct 24, 2022 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | Loading... | 
| Oct 24, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... | 
| Oct 24, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... | 
| Apr 9, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... | 
| Sep 15, 2018 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... | 
| Aug 24, 2018 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... | 
| Aug 24, 2018 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... | 
| Aug 15, 2018 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... | 
| May 15, 2018 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... | 
| Feb 27, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... | 
| Feb 27, 2018 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... | 
| Feb 22, 2018 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... | 
| Feb 7, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... | 
| Jan 25, 2018 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... | 
| Jan 25, 2018 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... | 
| Jan 25, 2018 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... | 
| Jan 25, 2018 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... | 
| Jan 25, 2018 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... | 
| Jan 22, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... | 
| Jan 22, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... | 
| Jan 18, 2018 | ALIE | A | ASSIGNED TO LIE | Loading... | 
| Jan 3, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... | 
| Oct 20, 2017 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... | 
| Oct 20, 2017 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... | 
| Aug 18, 2017 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... | 
| Aug 3, 2017 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... | 
| Aug 3, 2017 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... | 
| Aug 1, 2017 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... | 
| Aug 1, 2017 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... | 
| Jul 31, 2017 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... | 
| Jul 28, 2017 | DOCK | D | ASSIGNED TO EXAMINER | Loading... | 
| Jul 28, 2017 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... | 
| Jul 27, 2017 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... | 
| Jul 27, 2017 | LIMI | I | LIMITATION FROM ORIGINAL APPLICATION ENTERED | Loading... | 
Detailed Classifications
                                                Class 005
                                            
                                        Pharmaceutical [ and veterinary ] preparations, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues, all ] for use in human [ and veterinary ] medicine; Chemical preparations for pharmaceutical or medical purposes, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues, all for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Prescription and non-prescription ] medicines, [ namely, pills, tablets, capsules, caplets, liquid drops, sachets, and ] pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; ] Biological preparations for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; ] Biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues, all for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, and dermatology; Diagnostic preparations for medical purposes; ] Medicines for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; Organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; ] Biological reagents for medical use; Medicinal preparations based on cells and genes, namely, [ somatic cells, ] genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; [ Medicinal preparations based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; Products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, natural killer cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, ] products for gene therapy, namely, [ genetically modified cells, viral vectors, ] nucleic acids; [ Gene therapy products, namely, genetically engineered tissues for transplant purposes; Medicaments, namely, cells and tissues that have been subjected to extensive manipulation, to help assist with the regeneration of ligament and tendon fibers; ] Preparations for personalized medicine made of [ autologous cells or proteins or ] nucleic acids derived from individual genomic sequences; [ Preparations made up of cells for medical or clinical use; ] Preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes [ ; Preparations made up of tissues, namely, biological tissue cultures for medical purposes; Vaccines; Recombinant proteins supplements; Therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy ]
                                        
                                                Class 042
                                            
                                        Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; Research and development in the pharmaceutical and biotechnology fields; Research and development in the field of micro-organisms and cells; Research and development in the field of biochemistry; Scientific research and development in the field of biology; Research and development in the field of diagnostic preparations; Services of medical laboratories; Compiling medical information and data for research and development purposes in the medical and veterinary fields; Scientific and technological services, namely, scientific research and technical writing; Scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genitourinary, central nervous system, musculoskeletal, metabolic diseases, dermatology; Consultancy to ensure compliance with quality standards, the design and validation of manufacturing processes in the field of biology
                                        Additional Information
                                                
                                                Design Mark
                                            
                                        The mark consists of two side-by-side, touching circles, in which the circle on the right has two breaks. The circle on the left is light blue on the left, blue in the middle, and green on the right. The broken circle on the right is three quarters green and the separated one quarter portion is light gray.
                                    
                                                
                                                Color Claim
                                            
                                        The color(s) light blue, blue, green and light grey is/are claimed as a feature of the mark.
                                    Classification
                                            
                                            International Classes
                                        
                                        
                                                    005
                                                    042